Sterling Financial Hires Senior Biotech Analyst
Wednesday July 21, 12:40 pm ET
Dr. Paul Keough Adds to Biotechnology Coverage
MIAMI--(BUSINESS WIRE)--July 21, 2004--Sterling Financial Investment Group, Inc., today announced the hiring of Dr. Paul Keough as a Senior Biotechnology Analyst. Dr. Keough will support Sterling's Healthcare Equity Research Platform, and will focus on Biotechnology sector research. This addition reflects Sterling's continued efforts to expand its healthcare research practice, and is in concert with the firm's overall expansion of resources focused on the financial services industry.
Since being founded in 1997, Sterling Financial has emerged as one of the nation's premier research boutiques specializing in the health care sector. "The addition of Dr. Keough complements Sterling's healthcare-related coverage," says Alex Ryshawy, which includes Major Drug companies, Generics, Specialty Pharmaceuticals, and Biotechnology firms.
Prior to joining Sterling, Dr. Keough served as a Biotech Analyst at Lehman Brothers and at Wachovia Securities. Dr. Keough also screened startup Biotech companies for the Wolverine Venture Fund, a venture capital fund, and served as a Biotech consultant for TechStart and a health consultant at Medstat.
Dr. Keough earned his PhD in Biochemistry from Northwestern University and an MBA in Finance and Health Management from the University of Michigan Business School. He will be based in Chicago.
About Sterling
Founded in 1997 with just 3 employees, today Sterling Financial Investment Group Inc. has grown into a diversified full service international investment banking firm with more than 50 offices in 7 countries. In 2002, Sterling was named by Inc. magazine as the number 8 fastest growing privately held company in the United States. Sterling offers private client services, financial advisory, and fundamental research to both institutional and retail clients. Further information about Sterling can be found at mysterling.com. |
